Discovery of 4-morpholino-6-aryl-1H-pyrazolo[3,4-d]pyrimidines as highly potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): optimization of the 6-aryl substituent.

doi:10.1021/jm9013828

Paper

Discovery of 4-morpholino-6-aryl-1H-pyrazolo[3,4-d]pyrimidines as highly potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): optimization of the 6-aryl substituent.

Published Nov 6, 2009 · J. Verheijen, D. J. Richard, K. Curran

Journal of medicinal chemistry

Q1 SJR score

46

Citations

1

Influential Citations

Full textSemantic Scholar

Abstract

Design and synthesis of a series of 4-morpholino-6-aryl-1H-pyrazolo[3,4-d]pyrimidines as potent and selective inhibitors of the mammalian target of rapamycin (mTOR) are described. Optimization of the 6-aryl substituent led to the discovery of inhibitors carrying 6-ureidophenyl groups, the first reported active site inhibitors of mTOR with subnanomolar inhibitory concentrations. The data presented in this paper show that 6-arylureidophenyl substituents led to potent mixed inhibitors of mTOR and phosphatidylinositol 3-kinase alpha (PI3K-alpha), whereas 6-alkylureidophenyl appendages gave highly selective mTOR inhibitors. Combination of 6-alkylureidophenyl groups with 1-carbamoylpiperidine substitution resulted in compounds with subnanomolar IC(50) against mTOR and greater than 1000-fold selectivity over PI3K-alpha. In addition, structure based drug design resulted in the preparation of several 6-arylureidophenyl-1H-pyrazolo[3,4-d]pyrimidines, substituted in the 4-position of the arylureido moiety with water solubilizing groups. These compounds combined potent mTOR inhibition (IC(50) < 1 nM) with unprecedented activity in cellular proliferation assays (IC(50) < 1 nM).

In Vitro Study

Study Snapshot

Optimizing 6-aryl substituents in 4-morpholino-6-aryl-1H-pyrazolo[3,4-d]pyrimidines led to potent and selective inhibitors of mTOR with subnanomolar inhibitory concentrations, offering potential for cancer treatment.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Paper

Discovery of 4-morpholino-6-aryl-1H-pyrazolo[3,4-d]pyrimidines as highly potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): optimization of the 6-aryl substituent.

Sign up to use Study Snapshot

References

Citations

The role of PI3K-Akt-mTOR axis in Warburg effect and its modification by specific protein kinase inhibitors in human and rat inflammatory macrophages.

The Warburg effect in inflammatory macrophages is regulated by the PI3K-Akt-mTOR axis, and certain inhibitors of this pathway may be potential anti-inflammatory therapy candidates.

A review on macrocyclic kinase inhibitors in clinical trials

Macrocyclic kinase inhibitors show potential in treating various cancers, with ridaforomilus, pacritinib, and loratinib showing promise for breast cancer and advanced leukemia.

Design, Synthesis and Biological Evaluation of Novel Pleuromutilin Derivatives Containing 6-Chloro-1-R-1H-pyrazolo[3,4-d]pyrimidine-4-amino Side Chain

Novel pleuromutilin derivatives show good in vitro antibacterial ability against MRSA, with compound 22c showing faster bactericidal kinetics and longer PAE compared to tiamulin.

Discovery of novel (E)-1-methyl-9-(3-methylbenzylidene)-6,7,8,9-tetrahydropyrazolo[3,4-d]pyrido[1,2-a]pyrimidin-4(1H)-one as DDR2 kinase inhibitor: Synthesis, molecular docking, and anticancer properties.

PP562 shows excellent anticancer potency against HGC-27 gastric cancer cells, with its inhibitory effect on proliferation likely mediated through the DDR2 target.

Targeting tumor cells with pyrazolo[3,4-d]pyrimidine scaffold: A literature review on synthetic approaches, structure activity relationship, structural and target-based mechanisms

Pyrazolo[3,4-d]pyrimidine shows potential as an anticancer agent through binding with various receptors, and optimizing this ring system could lead to better selectivity and increased anticancer potential.

Chemical and Structural Strategies to Selectively Target mTOR Kinase

Selective ATP-competitive mTOR kinase inhibitors (TORKi) show promise for treating cancer and central nervous system disorders by targeting mTOR and its related pathways.

Virtual Screening and Optimization of Novel mTOR Inhibitors for Radiosensitization of Hepatocellular Carcinoma

A new class of selective mTOR inhibitors has been developed and confirmed to enhance the sensitivity of hepatocellular carcinoma to radiotherapy, offering potential for radiosensitization in HCC treatment.

Novel pyrazolo[3,4‐d]pyrimidine derivatives inhibit human cancer cell proliferation and induce apoptosis by ROS generation

PP-31d shows strong anticancer potential by inhibiting cancer cell growth and inducing apoptosis through reactive oxygen species generation.

Morpholine as ubiquitous pharmacophore in medicinal chemistry: Deep insight into the structure-activity relationship (SAR).

Morpholine ring is a versatile pharmacophore with diverse therapeutic activities, enhancing the potency of molecules through molecular interactions with target proteins or modulating pharmacokinetic properties.